Advertisement

Protocols for the Routine Screening of Drug Sensitivity in the Human Parasite Trichomonas vaginalis

  • Manal J. Natto
  • Anthonius A. Eze
  • Harry P. de Koning
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1263)

Abstract

Trichomonas vaginalis is a sexually transmitted protozoan parasite of humans. Treatment of trichomoniasis is almost completely dependent on the old drug metronidazole and is hampered by resistance. New drug development, like routine screening for drug resistance, has however been hampered by the lack of reliable screening protocols with sufficient throughput. Here we report on two separate in vitro protocols that use fluorescent dyes and allow for standardized drug sensitivity testing on the required scale.

Key words

Trichomonas vaginalis Trichomoniasis Drug screening High-throughput Drug resistance In vitro assay Resazurin Resorufin Propidium iodide Alamar Blue® 

Notes

Acknowledgements

This work was supported through a Research Fellowship from the Government of Saudi Arabia to M.J.N. (grant number S8306) and a Commonwealth scholarship to A.A.E.

References

  1. 1.
    Poole DN, McClelland RS (2013) Global epidemiology of Trichomonas vaginalis. Sex Transm Infect 89:418–422PubMedCrossRefGoogle Scholar
  2. 2.
    McClelland RS et al (2007) Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 195:698–702PubMedCrossRefGoogle Scholar
  3. 3.
    Cotch MF et al (1997) Trichomonas vaginalis associated with low birth weight and preterm delivery. Sex Transm Dis 24:353–360PubMedCrossRefGoogle Scholar
  4. 4.
    Bachmann LH et al (2011) Trichomonas vaginalis genital infections: progress and challenges. Clin Infect Dis 53(Suppl 3):S160–S172PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Dunne RL et al (2003) Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Res 13:239–249PubMedCrossRefGoogle Scholar
  6. 6.
    Miller MR, Nyirjesy P (2011) Refractory trichomoniasis in HIV-positive and HIV-negative subjects. Curr Infect Dis Rep 13:595–603PubMedCrossRefGoogle Scholar
  7. 7.
    Diamond LS (1957) The establishment of various trichomonads of animals and man in axenic cultures. J Parasitol 43:488–490PubMedCrossRefGoogle Scholar
  8. 8.
    Clark CG, Diamond LS (2002) Methods for cultivation of luminal parasitic protists of clinical importance. Clin Microbiol Rev 15:329–341Google Scholar
  9. 9.
    Giordani RB et al (2009) Anti-Trichomonas vaginalis activity of synthetic lipophilic diamine and amino alcohol derivatives. Biomed Pharmacother 63:613–617PubMedCrossRefGoogle Scholar
  10. 10.
    Campos Aldrete ME et al (2005) A high-throughput colorimetric and fluorometric microassay for the evaluation of nitroimidazole derivatives anti-Trichomonas activity. Toxicol In Vitro 19:1045–1050PubMedCrossRefGoogle Scholar
  11. 11.
    Duarte M et al (2009) A quantitative resazurin assay to determinate the viability of Trichomonas vaginalis and the cytotoxicity of organic solvents and surfactant agents. Exp Parasitol 123:195–198PubMedCrossRefGoogle Scholar
  12. 12.
    Natto MJ et al (2012) Validation of novel fluorescence assays for the routine screening of drug susceptibilities of Trichomonas vaginalis. J Antimicrob Chemother 67:933–943PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Manal J. Natto
    • 1
  • Anthonius A. Eze
    • 1
    • 2
  • Harry P. de Koning
    • 1
  1. 1.Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life SciencesUniversity of GlasgowGlasgowUK
  2. 2.Department of Medical BiochemistryUniversity of NigeriaEnuguNigeria

Personalised recommendations